Verastem, Inc. Delivers Strong 2025 Results and Advances Promising Oncology Pipeline into 2026

Key Financial and Clinical Highlights for Investors

• FDA Approval and Commercial Launch: Verastem received FDA approval for AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of KRAS-mutated recurrent Low-Grade Serous Ovarian Cancer (LGSOC) on May 8, 2025, two months ahead of the PDUFA date. This marks the first novel/novel combination therapy targeting the RAS/MAPK pathway approved in oncology.
• Strong Launch Performance: Net product revenue for May–December 2025 reached \$30.9 million, with \$17.5 million in Q4 alone. This was driven by robust uptake among both academic and community oncologists, a 60/40 split between GynOncs and MedOncs, and rapid payer coverage resulting in a 12–14 day time-to-fill window.
• Expanding Clinical Pipeline: Verastem is advancing a multi-faceted RAS/MAPK-driven cancer pipeline, including pivotal Phase 3 trials and a best-in-class KRAS G12D inhibitor (VS-7375) targeting high-unmet-need solid tumors such as pancreatic, lung, and colorectal cancers.
• Upcoming Catalysts: Several high-impact readouts are expected in 2026, including early data from the VS-7375-101 Phase 1/2 trial in 1H 2026, an update from the RAMP 205 1L metastatic pancreatic cancer cohort in Q2 2026, and the completion of combination dose escalation cohorts for VS-7375 in mid-2026.
• Balance Sheet Strength: Cash, cash equivalents, and short-term investments stood at \$205 million at year-end 2025, with a pro-forma figure of \$234.4 million after January 2026 warrant exercises. The company’s Oberland Finance credit facility provides up to \$150 million in non-dilutive capital, with \$75 million currently drawn and further tranches available upon hitting commercial milestones.
• Cash Runway: Verastem expects its cash runway to extend into 2027, supporting the continued commercialization of AVMAPKI FAKZYNJA CO-PACK and advancement of its clinical programs.

Details Investors Need to Know

Commercial Execution and Market Penetration

Verastem’s commercial launch of AVMAPKI FAKZYNJA CO-PACK has been highly successful, with approximately 300 prescribers through February 2026 and adoption among 75% of top target institutions. The company has invested in comprehensive educational programs, patient support, and peer-to-peer initiatives to drive new patient starts and support ongoing therapy use.

Regulatory and Clinical Development Milestones

• RAMP 301 Confirmatory Phase 3 Trial: Fully enrolled and expected to deliver topline progression-free survival (PFS) data by mid-2027. The trial is designed to confirm and expand the U.S. label for AVMAPKI FAKZYNJA CO-PACK to include all recurrent LGSOC patients, regardless of KRAS mutation status, and to support approvals in Europe and Japan.
• VS-7375 (KRAS G12D Inhibitor): This asset could be a potential best-in-class therapy given its dual ON/OFF inhibition, high affinity, long residence time (18–24 hours), and strong monotherapy response rates in both pancreatic (58.3% ORR in 2L) and NSCLC (68.8% ORR in 2L) in Chinese studies. The U.S. program has cleared multiple dose levels without dose-limiting toxicities and is expanding into monotherapy and combination cohorts in 2026, with plans for registration-directed Phase 2 trials in PDAC, NSCLC, and CRC.
• Pancreatic Cancer Combination Therapy (RAMP 205): Updated data from ASCO 2025 showed an 83% confirmed ORR in first-line metastatic pancreatic cancer, with manageable side effects and promising durability, positioning the combination as a potential new standard of care.

Competitive Position and Market Opportunity

Verastem’s focus on the RAS/MAPK pathway directly addresses a major oncogenic driver across multiple solid tumors. With approximately 70% of LGSOC tumors driven by this pathway, and 30% harboring a KRAS mutation, the company is well-positioned to expand its label and geographic reach. The KRAS G12D inhibitor opens a multi-billion-dollar market opportunity across pancreatic, lung, colorectal, and other solid tumors with high unmet need and poor prognosis.

Financial Position and Guidance

• Q4 2025 GAAP operating expenses were \$59.0 million (non-GAAP: \$57.0 million), with full-year 2025 GAAP expenses at \$201 million (non-GAAP: \$191.6 million).
• Access to up to \$150 million in credit from Oberland Finance, with no financial covenants and interest-only payments through January 2031.
• Cash runway expected through key data readouts into 2027, with the AVMAPKI FAKZYNJA CO-PACK franchise expected to be self-sustaining in 2H 2026.

Potentially Price-Sensitive Information

• Accelerated FDA approval and rapid uptake of AVMAPKI FAKZYNJA CO-PACK provide a strong commercial foundation and validate the company’s RAS/MAPK pathway strategy.
• Multiple upcoming clinical catalysts in 2026 and 2027, including pivotal readouts and label expansion opportunities, could drive further share price appreciation if positive.
• VS-7375’s best-in-class potential and broad applicability across KRAS G12D-driven tumors create a significant value creation opportunity.
• Financial strength and non-dilutive capital access reduce financing risk and support pipeline development without excessive shareholder dilution.

Risks and Forward-Looking Statements

Verastem’s outlook includes numerous forward-looking statements and is subject to development risks, regulatory uncertainties, competition, and the possibility that clinical and commercial milestones may not be achieved as planned.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. The outlook for Verastem, Inc. involves significant risks and uncertainties, including but not limited to clinical trial results, regulatory approvals, commercialization success, and market adoption. Investors should review all company filings and consult their own advisors before making investment decisions.

View Verastem, Inc. Historical chart here